Research Paper Volume 12, Issue 24 pp 25275—25293

DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications

Figure 2. Construction of the prognostic methylation model for patients with LUAD. (A) The clustering analysis heatmap of methylation profile in DNA methylation signature sites. (B) The distribution of DNA methylation-based risk score. (C) Vital status of patients in the high- and low-risk groups. (D) Kaplan–Meier survival curves of the relative overall survival of patients in the high- and low-risk groups. (E) Accuracy of the prognostic model in predicting survival time by time-dependent ROC curve analysis. LUAD, lung adenocarcinoma; ROC, receiver operating characteristic.